# Efficacy of Alphanate FVIII/VWF Concentrate in Type 3 Von Willebrand Patients

> **NCT00555555** · PHASE4 · ACTIVE_NOT_RECRUITING · sponsor: **Grifols Biologicals, LLC** · enrollment: 15 (estimated)

## Conditions studied

- Von Willebrand Disease

## Interventions

- **BIOLOGICAL:** Alphanate SD/HT

## Key facts

- **NCT ID:** NCT00555555
- **Lead sponsor:** Grifols Biologicals, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2007-09
- **Primary completion:** 2028-12
- **Final completion:** 2029-03
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2023-08-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00555555

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00555555, "Efficacy of Alphanate FVIII/VWF Concentrate in Type 3 Von Willebrand Patients". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00555555. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*